Merck&Co., Inc., an American multinational biopharmaceutical company, has entered into an agreement to acquire the rights to the experimental drug HRS-5346, developed by China's Jiangsu Hengrui ...

MRK in-licenses an experimental lipoprotein(a) inhibitor from China's Jiangsu Hengrui. This transaction is expected to be ...

MSD will pay Hengrui Pharma $200m upfront, up to $1.77bn in development, regulatory and commercial milestones, and royalties ...

Hengrui Pharma signs exclusive licensing agreement for its heart disease drug with Merck & Co.

Merck & Co – known as MSD outside the US and Canada – has said it will be gaining exclusive global rights to Jiangsu Hengrui ...

Hengrui Pharma signed the agreement with Merck (NYSE: MRK) — known as MSD outside of the United States and Canada — for HRS-5346, its investigational oral small molecule Lipoprotein (a), or Lp (a), ...

The deal gives MSD exclusive rights to the HRS-5346 candidate outside the Greater China region and also includes milestone payments tied to development, regulatory, and commercial targets that ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a ...